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ABSTRACT 
Rationale: Pro-inflammatory cytokines have been identified as potential targets for lowering vascular risk. 
Experimental evidence and Mendelian randomization suggest a role of monocyte-chemoattractant protein-
1 (MCP-1) in atherosclerosis and stroke. However, data from large-scale observational studies are lacking. 
Objective: To determine whether circulating levels of MCP-1 are associated with risk of incident stroke in 
the general population. 
Methods and Results: We used previously unpublished data on 17,180 stroke-free individuals (mean age 
56.7±8.1 years; 48.8% males) from six population-based prospective cohort studies and explored 
associations between baseline circulating MCP-1 levels and risk of any stroke, ischemic stroke, and 
hemorrhagic stroke over a mean follow-up interval of 16.3 years (280,522 person-years at risk; 1,435 
incident stroke events). We applied Cox proportional hazard models and pooled hazard ratios (HR) using 
random-effects meta-analyses. Following adjustments for age, sex, race, and vascular risk factors, higher 
MCP-1 levels were associated with increased risk of any stroke (HR per 1 SD increment in ln-transformed 
MCP-1: 1.07, 95%CI: 1.01-1.14). Focusing on stroke subtypes, we found a significant association between 
baseline MCP-1 levels and higher risk of ischemic stroke (HR: 1.11, [1.02-1.21]), but not hemorrhagic 
stroke (HR: 1.02, [0.82-1.29]). The results followed a dose-response pattern with a higher risk of ischemic 
stroke among individuals in the upper quartiles of MCP-1 levels as compared to the 1st quartile (HRs: 2nd 
quartile: 1.19 [1.00-1.42]; 3rd quartile: 1.35, [1.14-1.59]; 4th quartile: 1.38, [1.07-1.77]). There was no 
indication for heterogeneity across studies and in a sub-sample of four studies (12,516 individuals) the risk 
estimates were stable after additional adjustments for circulating levels of interleukin-6 and high-sensitivity 
C-reactive protein. 
Conclusions: Higher circulating levels of MCP-1 are associated with increased long-term risk of stroke. 
Our findings along with genetic and experimental evidence suggest that MCP-1-signaling might represent 
a therapeutic target to lower stroke risk. 
Keywords:  
Monocyte chemoattractant protein-1; CCL2; stroke; cerebrovascular disease/stroke; atherosclerosis; 
chemokine; inflammation. 
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INTRODUCTION 
Stroke is the leading cause of adult disability and the second most common cause of death 
worldwide.1, 2 Inflammatory mechanisms contribute to the pathogenesis of stroke, most notably to large 
artery atherosclerotic stroke,3, 4 but the specific pro-inflammatory factors mediating stroke risk are largely 
elusive. Discordant results from the CANTOS5-8 and CIRT6 randomized controlled trials emphasize the 
importance of targeting specific mediators and pathways for lowering vascular risk.5-8 Treatment with an 
anti-interleukin-1β (IL-1β) monoclonal antibody reduced the levels of IL-6 and high-sensitivity C-reactive 
protein (hsCRP) leading to a reduction in the combined primary endpoint of nonfatal myocardial infarction, 
nonfatal stroke or cardiovascular death independent of low-density lipoprotein (LDL) cholesterol levels,5 
whereas treatment with low-dose methotrexate neither reduced cardiovascular event rates nor the levels of 
IL-1β, IL-6, and hsCRP.6   
In a Mendelian Randomization study on circulating levels of 41 cytokines and growth factors, we 
recently found genetic predisposition to higher levels of the CC-chemokine monocyte-chemoattractant 
protein-1 (MCP-1; also known as CC-chemokine ligand 2, CCL2) to be associated with increased risk of 
stroke, ischemic stroke, coronary artery disease, and myocardial infarction.9 MCP-1 recruits monocytes to 
the subendothelial space of the atherogenic arterial wall10-12 and studies in experimental models of 
atherosclerosis suggest that targeting MCP-1 or its receptor CCR2 limits plaque size, plaque progression, 
and plaque destabilization.13-17 These findings define the MCP-1/CCR2 axis as a potential additional target 
for reducing residual inflammatory risk in vascular disease. However, data on MCP-1 and vascular risk in 
humans remain scarce.  
Among patients with acute coronary syndromes in the OPUS-TIMI 1618 and A to Z trial,19 high 
circulating MCP-1 levels were associated with a significantly increased risk of death or myocardial 
infarction during follow-up, independently of baseline variables including hsCRP levels. In population-
based studies higher MCP-1 levels were associated with subclinical atherosclerosis and incident coronary 
artery disease during follow-up.20, 21 In contrast, the relationship between circulating MCP-1 levels and 
incident stroke remains unknown as does the relationship between MCP-1, IL-6, and CRP in mediating 
vascular risk. 
Here, leveraging data from six population-based prospective cohort studies encompassing 17,180 
stroke-free individuals with long-term follow-up, we set out to: (i) determine the association between 
circulating MCP-1 levels at baseline and risk of incident stroke, (ii) explore associations of MCP-1 levels 
with risk of major stroke subtypes (incident ischemic and hemorrhagic stroke), and (iii) assess whether 
any association with stroke risk is independent of the IL-6 and CRP axis by adjusting for the circulating 
levels of IL-6 and hsCRP. 
METHODS 
This study is based on summary statistics produced by the studies included in the systematic review. The 
main individual-study results are provided as Supplemental material. All summary data that support the 
findings of this study are further available from the corresponding author upon reasonable request. For 
accessing individual-level data of the included studies the readers should contact the authors representing 
the respective studies and follow the required processes. 
Systematic review. 
We systematically searched PubMed from inception through 15 March 2019 for population-based 
prospective cohort studies exploring associations between circulating MCP-1 levels and the risk of incident 
vascular outcomes including coronary artery disease, myocardial infarction, fatal or non-fatal stroke, and 
peripheral artery disease. The reference lists of the identified studies were further hand searched. The 
detailed search strategy is available in the Appendix. We subsequently contacted the corresponding authors 
of the selected studies inquiring about their interest to contribute data for the current meta-analysis 
examining the association between circulating MCP-1 levels and risk of incident stroke. Investigators of 
the following six studies agreed to participate and the following studies were thus included in the current 
meta-analysis: the Atherosclerosis Risk in Communities (ARIC) Study,20 the Dallas Heart Study (DHS),21 
the  Norfolk arm of the European Prospective Investigation of Cancer (EPIC-Norfolk) study,22 the Offspring 
Cohort of the Framingham Heart Study (FHS),23 the Monitoring of Trends and Determinants in 
Cardiovascular Disease (MONICA) subcohort of the Kooperative Gesundheitsforschung in der Region 
Augsburg (KORA) study,24 and the cardiovascular subcohort of the Malmö Diet and Cancer Study 
(MDCS).25 With the exception of the FHS Offspring study, which had previously published part of the data 
included in this analysis (96 vs 172 incident events)23, none of the studies previously published data on the 
association between circulating MCP-1 levels and risk of incident stroke. The flowchart describing the 
study selection is depicted in Online Figure I. 
Study populations, MCP-1 level measurements and assessment of stroke outcomes. 
The study design, population characteristics, methods used for quantifying circulating MCP-1 levels, stroke 
outcome definitions, and assessments in individual cohorts are detailed in Online Table I. In brief, all 
studies were population-based prospective cohorts and participants included in the current analyses were 
selected from these cohorts based on availability of MCP-1 measurements at baseline. Circulating MCP-1 
levels were measured in serum or plasma samples drawn during the baseline assessments. As incident stroke 
was the primary outcome of the current study, all participants with a history of stroke at baseline 
assessments (prevalent cases) were excluded from subsequent analyses. Stroke occurrence was assessed 
during follow-up visits over mean intervals of 11 to 23 years based on self-reported information and 
validation from medical records of the participants. In addition to information on any stroke, all studies 
further provided information on the major stroke subtypes (ischemic vs hemorrhagic stroke). 
Quality assessment. 
Study quality was assessed using the cohort subscale of the Newcastle-Ottawa scale.26 The criteria for 
awarding quality points were the following: a general population sample (representativeness of exposed 
cohort); selection of patients for inclusion independently of MCP-1 levels (selection of the non-exposed 
cohort); measurement of MCP-1 levels in the serum or plasma based on a validated assay (ascertainment 
of exposure); exclusion of patients with prevalent stroke at baseline (outcome not present at start of study); 
adjustments for age and sex, as well as for conventional vascular risk factors (comparability items); 
assessment of stroke outcomes blindly to MCP-1 levels with validation based on medical records 
(assessment of outcome); a follow-up interval longer than 5 years (follow-up duration); and a completion 
of follow-up rate of >90% (adequacy of follow-up cohorts). 
Statistical analysis. 
A pre-defined analysis protocol was circulated to investigators of each of the cohort studies requesting 
summary results for meta-analysis. MCP-1 levels were ln-transformed in all studies for normalization. We 
did not consider absolute MCP-1 values due to marked differences in mean MCP-1 level values between 
studies, probably related to different assays used for MCP-1 quantification (Table 1). We first examined 
descriptive associations between MCP-1 levels and conventional vascular risk factors. We pooled study-
specific z-scores reflecting differences of MCP-1 levels from the overall mean of each study with random-
effects models across the risk factor categories and statistically examined associations using meta-
regression.  
To examine associations between baseline MCP-1 levels and incident stroke, Cox proportional hazard 
models were fit in each study. MCP-1 levels were included in the models as either a continuous variable (1 
SD increment in ln-transformed MCP-1 levels) or categorized in 4 quartiles (1st quartile as reference 
category) to also assess for potential non-linear associations. We applied three models with different levels 
of adjustments: model 1 was adjusted for age, sex, and race; model 2 was additionally adjusted for 
conventional vascular risk factors (hypertension, diabetes mellitus, hypercholesterolemia, body mass index 
[BMI], smoking [current vs. non-current], estimated glomerular filtration rate [eGFR], coronary artery 
disease, atrial fibrillation, and heart failure); and model 3 was further adjusted for circulating hsCRP levels 
on top of these variables. Model 2 was pre-defined as our main model for analyses. In these models, we 
defined hypertension as a history of physician-diagnosed hypertension, systolic blood pressure (SBP) ≥140 
mmHg, diastolic blood pressure (DBP) ≥90 mmHg, or use of one or more antihypertensive medications.27 
We defined diabetes mellitus as a history of physician-diagnosed diabetes mellitus, glycosylated 
hemoglobin type A1C (HbA1c) ≥6.5%, fasting glucose ≥126 mg/dL, random glucose levels ≥200 mg/dL, 
or use of glucose-lowering medications.28 Hypercholesterolemia was defined as LDL cholesterol levels 
≥130 mg/dL, total cholesterol levels ≥200 mg/dL (if LDL cholesterol not available) or use of lipid-lowering 
drugs,29 and chronic kidney disease as eGFR <60 ml/min/1.73 m2.30 In an alternative model (alternative 
model 2), we directly adjusted for the components of these definitions instead of the binary variables: thus, 
instead of hypertension, diabetes mellitus, hypercholesterolemia, and chronic kidney disease, we included 
SBP (as continuous variable), use of antihypertensive medications, fasting glucose levels (as continuous), 
use of glucose-lowering medications, LDL cholesterol levels (as continuous), administration of lipid-
lowering medications, and eGFR (as continuous). 
The purpose of the main models was to explore MCP-1 as a potentially causal risk factor for stroke and not 
to evaluate the predictive values of its levels. In subsequent models, we aimed to explore whether the 
association between MCP-1 levels and risk of stroke is independent of the IL-6/CRP pathway that was 
recently shown to provide an efficient drug target for reducing vascular risk.31 To indirectly examine this, 
we applied additional adjustments for circulating IL-6 and hsCRP levels. In one model, we included IL-6 
on top of age, sex, race, and vascular risk factors, and in a subsequent model we included both IL-6 and 
hsCRP levels. We did this because CRP is a downstream effector of IL-6, but also comprises a more general 
marker of inflammation, and thus the alternative adjustments provide different levels of information 
regarding the involved inflammatory pathways. Data for IL-6 circulating levels were not available in ARIC 
and the EPIC-Norfolk. Thus, these cohorts were not included in these analyses.  
Analyses were conducted separately for any stroke, ischemic stroke, and hemorrhagic stroke. DHS was 
excluded from the analysis for hemorrhagic stroke, where MCP-1 was examined in quartiles, due to the 
low numbers of incident events across the quartile categories of MCP-1 levels. The hazard ratios (HR) and 
the 95% confidence intervals (95%CIs) derived from each study were pooled with random-effects 
(DerSimonian-Laird) meta-analyses to allow for heterogeneity across studies related to the different 
baseline characteristics and the different methods of MCP-1 assessment. Heterogeneity across studies was 
assessed with the I2 and the Cochran’s Q statistic (I2 >50% and p<0.10 were considered statistically 
significant).  
To examine whether the pooled risk estimates were driven by any individual study, we also applied 
sensitivity analyses by pooling the risk estimates across studies after excluding one study at a time. To 
explore potential interactions between MCP-1 levels and known cardiovascular risk factors, we performed 
meta-regression analyses examining how the prevalence of cardiovascular risk factors or the mean or 
median values of biomarkers, were associated with the risk estimates for stroke in each study. We further 
performed subgroup analyses by sex, presence of hypertension, presence of diabetes mellitus, and BMI 
levels (<30 vs. ≥30 kg/m2). Differences in the effect sizes across the subgroup categories were examined 
by assessing heterogeneity (I2 >50% and p<0.10 were considered statistically significant). Finally, we 
performed separate analyses for fatal and non-fatal stroke (fatal stroke defined as death occurring within 30 
days after the stroke event). 
Statistical significance was set at a two-sided p-value <0.05 for the main analysis for any stroke. For the 
subsequent analysis for stroke subtypes, we corrected for multiple comparisons based on the Bonferroni 
method (p <0.05/2 stroke subtypes=0.025). Finally, we corrected for multiple comparisons in the 
descriptive analyses exploring the correlations between MCP-1 levels and baseline variables (threshold for 
statistical significance at p <0.05/12 variables=0.004). All analyses were conducted with SAS (v9.4) and 
Stata (v13.0).  
RESULTS 
Following a systematic review and contact with the lead investigators, six population-based 
prospective cohort studies contributed previously unpublished data for this meta-analysis. All studies 
scored high in quality as they fulfilled the full set of Newcastle-Ottawa scale criteria (Online Table II). 
The baseline characteristics of each study are presented in Table 1. In total, 17,180 individuals (mean age 
56.7 ± 8.1 years; 48.8% males), who were stroke-free at baseline, were followed for a mean interval of 16.3 
years (range of mean follow-up: 11 to 23 years) with 280,522 person-years at risk. A total of 1,435 incident 
stroke cases were diagnosed during follow-up, which were classified as ischemic in 1,233 cases and as 
hemorrhagic in 205 cases. Two hundred twenty-six (15.7%) of the incident stroke events were fatal. Median 
MCP-1 levels differed between studies possibly reflecting differences in the methods used for MCP-1 
quantification (Online Table I). Figure 1 displays associations of standardized MCP-1 levels with 
conventional vascular risk factors in the pooled sample. We found the following baseline factors to be 
associated with higher circulating MCP-1 levels: older age, male sex, higher systolic blood pressure, 
presence of diabetes mellitus, higher LDL cholesterol levels, higher HDL cholesterol levels, higher BMI, 
current smoking, lower estimated glomerular filtration rate (eGFR), history of coronary artery disease 
(CAD), higher hsCRP levels, and higher IL-6 levels.  
In the pooled analysis, we found higher MCP-1 levels at baseline to be associated with an increased 
risk of any stroke both in a model adjusted for age, sex, and race (model 1: HR per 1 SD increment in ln-
transformed MCP-1: 1.10, 95%CI: 1.01-1.19, p=0.02) and in the main model further adjusted for vascular 
risk factors (model 2, HR: 1.07, 95%CI: 1.01-1.14, p=0.03) (Figure 2 and Online Table III). In analyses 
comparing MCP-1 quartiles, we found the association between MCP-1 levels and risk of stroke to follow a 
dose-response pattern with a higher risk among individuals in the upper quartiles of circulating MCP-1 
levels as compared to the 1st quartile (HRs from model 2: 2nd quartile, 1.16, 95%CI: 0.99-1.36, p=0.07; 3rd 
quartile 1.31, 95%CI: 1.12-1.53; p=0.001; 4th quartile, 1.33, 95%CI: 1.05-1.68; p=0.008). The results were 
further stable in a model additionally adjusting for circulating hsCRP levels (model 3 in Figure 2 and 
Online Table III). 
We next examined the associations of circulating MCP-1 levels at baseline with stroke subtypes 
(Figure 3 and Online Table III) and found significant associations of higher MCP-1 levels at baseline with 
the risk of ischemic stroke (HR per 1 SD increment in ln-MCP-1 from model 2: 1.11, 95%CI: 1.02-1.21, 
p=0.009), but not with hemorrhagic stroke (model: HR: 1.02, 95%CI: 0.82-1.29, p=0.83). MCP-1 levels in 
the 2nd, 3rd, and 4th quartiles, as compared to the 1st, were associated with a higher risk for ischemic stroke 
after adjusting for age, sex, race, and vascular risk factors (model 2, HRs: 2nd quartile, 1.19, 95%CI: 1.00-
1.42, p=0.05; 3rd quartile 1.35, 95%CI: 1.14-1.59; p<0.001; 4th quartile, 1.38, 95%CI: 1.07-1.77; p=0.008). 
The results were highly consistent in the model additionally adjusting for circulating hsCRP levels on top 
of the vascular risk factors (model 3 in Figure 3 and Online Table IV). 
Study-specific risk estimates are depicted in Online Figures II-IV. There was no evidence of 
heterogeneity in any of the analyses (I2 <50% and Cochran Q-derived p>0.10), except for moderate 
heterogeneity in the analysis of the upper 4th MCP-1 quartile for any stroke and ischemic stroke (I2=49.8%; 
p=0.08 and I2=46.1%; p=0.10, respectively). The results were similar for both fatal and non-fatal stroke 
(I2=0% for between-subgroup comparisons), although the confidence intervals for fatal stroke were wider 
probably because of lower statistical power (Online Figure V). The association estimates remained 
consistent in alternative models directly adjusting for the crude components of vascular risk factors (SBP, 
fasting glucose levels, LDL cholesterol, eGFR) and use of antihypertensive, glucose-lowering, or lipid-
lowering medications (alternative model 2; Online Tables III-V). Furthermore, the results remained stable 
in sensitivity analyses omitting one study per time (leave-one-out analysis) showing that the results were 
not driven by any individual study (Online Figures VI-VIII). Meta-regression analyses showed that none 
of the examined study population characteristics nor the sample source (serum vs. plasma) modified the 
associations of MCP-1 with the risk of any stroke, ischemic stroke, or hemorrhagic stroke (Online Table 
VI). Finally, in subgroup analyses stratifying for sex, hypertension, diabetes mellitus, and BMI (≥30 vs. 
<30 kg/m2) there was no indication for heterogeneity in the risk estimates for any stroke, ischemic stroke, 
and hemorrhagic stroke between subgroups (I2=0%) (Online Figure IX). 
As a last step, we performed analyses with additional adjustments for IL-6 and hsCRP levels in 
four studies (12,516 individuals; 758 incident stroke events) with available data. Adjustment for IL-6 levels 
showed that the risk estimates between MCP-1 levels and risk of stroke and stroke subtypes remained stable, 
although with wider confidence intervals than the main analysis, as would be expected given the smaller 
sample sizes (Online Table VII). Similarly, simultaneous adjustments for both IL-6 and hsCRP did not 
alter the risk estimates between MCP-1 and risk of stroke or stroke subtypes, even though both variables 
were associated with the risk of any stroke and ischemic stroke (Online Table VII). 
DISCUSSION 
Pooling data from six population-based cohort studies involving 17,180 stroke-free individuals, we 
found higher circulating levels of MCP-1 at baseline to be associated with a higher long-term risk of stroke 
after accounting for age, sex, race, and vascular risk factors. In analyses for stroke subtypes, MCP-1 levels 
were specifically associated with the risk of ischemic stroke, but not with hemorrhagic stroke. These 
associations followed a dose-response pattern and risk estimates were stable after additional adjustments 
for serum levels of IL-6 or hsCRP.   
Our results, which were obtained in studies with long-term follow-up, confirm and extend our 
recent Mendelian randomization finding of a higher stroke risk among individuals with genetic 
predisposition to higher lifetime MCP-1 levels.9 The results were remarkably consistent between the two 
approaches: with Mendelian randomization the odds ratio for stroke was 1.06 per SD increment in 
genetically determined MCP-1 levels, which is almost identical to the hazard ratio for incident stroke 
observed in the current meta-analysis of observational studies. In accord with the Mendelian randomization 
results, higher MCP-1 levels were further associated with a higher risk of incident ischemic stroke, but not 
hemorrhagic stroke, which is consistent with the established role of MCP-1 in experimental atherosclerosis. 
The magnitude of association of MCP-1 with incident ischemic stroke was modest suggesting that MCP-1 
measurement is not likely to be of value as a risk marker for stroke although this would need to be formally 
examined. Of note however, risk estimates compare well with those for lipoprotein (a),32, 33 which is 
established as a causal risk factor for atherosclerosis currently under investigation in clinical trials.34, 35  
When viewed together with the genetic9 and experimental data13-17 our findings provide triangulation of 
evidence regarding a role of MCP-1 as a causal risk factor for stroke. 
Only limited human data exist supporting vascular benefits by reducing inflammation. Secondary 
analyses from the CANTOS trial showed that the reductions in vascular event rates after IL-1β inhibition 
were restricted to individuals with a substantial decrease in IL-6 or hsCRP levels.31, 36 Importantly, the risk 
estimates for stroke by MCP-1 levels in our study remained stable after additional adjustments for the 
baseline levels of IL-6, hsCRP, and both IL-6 and hsCRP. This observation provides indirect evidence 
suggesting that elevated levels of MCP-1 might influence risk of stroke independently of the IL-1β/IL-
6/CRP axis. Thus, targeting the MCP-1/CCR2 pathway might serve as an alternative anti-inflammatory 
strategy with independent and complementary effects in reducing vascular event rates on top of current 
approaches. 
Deficiency of either MCP-115, 17 or its receptor CCR216 decreases plaque burden and limits lipid 
deposition and macrophage infiltration in experimental models of atherosclerosis. Similar effects are 
observed with pharmacological treatment using MCP-1 competitors13 or CCR2 antagonists.14, 37-39 In 
contrast, overexpression of MCP-1 promotes oxidized lipid accumulation, macrophage infiltration, and 
smooth muscle cell proliferation, thus accelerating atheroscleoris.40  To our knowledge, there has been only 
one small phase II randomized controlled trial in the context of atherosclerosis in humans that targeted the 
MCP-1/CCR2 axis. Among 108 patients with cardiovascular risk factors and hsCRP levels >3 mg/L, those 
treated with a single intravenous infusion of MLN1202, a humanized monoclonal antibody against CCR2, 
exhibited significant reductions in hsCRP levels after 4 weeks and continuing through 12 weeks after 
dosing.41 However, this study did not assess clinical outcomes, which would need to be examined in a larger 
trial.41  
Our study has several strengths. The pooled analysis was based on a large sample size of >17,000 
individuals from six previously unpublished population-based prospective studies with long follow-up 
intervals and a large number of incident events, thus providing sufficient statistical power to identify robust 
associations. The included studies fulfilled all of the criteria of quality assessment, which minimized the 
risk of several sources of bias. We further applied extensive adjustments for demographic and vascular risk 
factors thus accounting for confounding and enabling the identification of independent associations 
between MCP-1 levels and risk of stroke. Finally, in four of the cohorts we had available data on IL-6 and 
hsCRP measurements, which allowed examining the associations between MCP-1 and stroke after 
adjusting for these biomarkers. 
Our study also has limitations. First, the different assays used by individual studies to quantify 
circulating MCP-1 levels and the different sample sources (plasma vs. serum) resulted in substantial 
variations in MCP-1 levels between studies. Although our analyses standardized MCP-1 levels across 
studies, it was not possible to explore associations between absolute MCP-1 values and risk of stroke. 
Second, studies differed in terms of demographic characteristics and prevalence of vascular risk factors. 
While we found no evidence of substantial heterogeneity between studies, there was moderate 
heterogeneity in the analyses for the highest quartiles of MCP-1, which could possibly be explained by the 
differences in baseline MCP-1 levels and in vascular risk profiles between studies. Third, we could not 
explore associations between MCP-1 levels and risk of ischemic stroke subtypes (large artery, 
cardioembolic, small vessel stroke) as information on deeper phenotyping was not available for the majority 
of studies. Fourth, our analyses were based on predominantly European ancestry individuals, and do thus 
not necessarily apply to other ethnic groups. Fifth, we cannot exclude residual confounding. Finally, based 
on our a priori determined approach and power calculations, we corrected for multiple comparisons within 
each level of analysis but not across all analyses. Although this would not be expected to have any impact 
on the findings, future studies with even larger sample sizes would be useful in replicating our results 
In conclusion, this meta-analysis demonstrates that higher circulating levels of MCP-1 among 
stroke-free individuals are associated with increased long-term risk of ischemic stroke. The results extend 
and corroborate experimental and genetic evidence suggesting a key role of MCP-1 in atherosclerosis and 
stroke. Additional work is needed to examine whether interventions aimed at interfering with MCP-1 
signaling would lower stroke risk. 
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FIGURE LEGENDS 
Figure 1. Cross-sectional associations between baseline circulating MCP-1 levels, demographic factors, 
conventional vascular risk factors, and inflammatory biomarkers. Shown are the results from the pooled 
sample consisting of six population-based studies. 
* statistically significant results (after correction for multiple comparisons statistical significance was set
at p <0.05/12=0.004). 
** <40 and 40-59 mg/dL for men, <50 and 50-59 mg/dL for women. 
Z-score for circulating MCP-1 levels correspond to differences from the mean value of each study. P-values 
are derived from meta-regression. 
Abbreviations: BMI, body mass index; HDL, high-density lipoprotein; hsCRP, high-sensitivity C-reactive 
protein; eGFR, estimated glomerular filtration rate; LDL, low-density lipoprotein; MCP-1, monocyte 
chemoattractant protein- 1; SBP, systolic blood pressure.   
Figure 2. Associations between baseline circulating MCP-1 levels and risk of any stroke. Shown are the 
results from random-effects meta-analyses of the pooled sample consisting of six population-based studies. 
Model 1 is adjusted for age, sex, and race. Model 2 is adjusted for age, sex, race, and vascular risk factors 
including body mass index (1 kg/m2 increment), smoking (current vs. non-current), estimated glomerular 
filtration rate (1 mL/min/1.73 m² increment), history of coronary artery disease, diabetes mellitus, 
hypercholesterolemia, hypertension, atrial fibrillation, and heart failure at baseline. Model 3 is additionally 
adjusted for circulating high-sensitivity C-reactive protein (hsCRP) levels.  
Analyses for 1 SD increment correspond to ln-transformed MCP-1 levels.  
Figure 3. Associations between baseline circulating MCP-1 levels and risk of (A) ischemic stroke and (B) 
hemorrhagic stroke. Shown are the results from random-effects meta-analyses of the pooled sample 
consisting of six population-based studies. 
* Statistical significance threshold was set at p <0.05/2=0.025 after correction for multiple comparisons (two
stroke subtypes).  
Model 1 is adjusted for age, sex, and race. Model 2 is adjusted for age, sex, race, and vascular risk factors 
including body mass index (1 kg/m2 increment), smoking (current vs. non-current), estimated glomerular 
filtration rate (1 mL/min/1.73 m² increment), history of coronary artery disease, diabetes mellitus, 
hypercholesterolemia, hypertension, atrial fibrillation, and heart failure at baseline. Model 3 is additionally 
adjusted for circulating high-sensitivity C-reactive protein (hsCRP) levels.  
Analyses for 1 SD increment correspond to ln-transformed MCP-1 levels.  
NOVELTY AND SIGNIFICANCE 
What Is Known? 
 Inflammatory mechanisms contribute to the pathogenesis of vascular disease and inflammatory
cytokines have been identified as potential therapeutic targets for lowering vascular risk.
 Using genetic data, we recently showed in Mendelian randomization that lifetime higher
monocyte-chemoattractant protein 1 (MCP-1) levels are associated with a higher risk of ischemic
stroke.
 Preclinical studies in animal models of experimental atherosclerosis further suggest a critical role
of MCP-1 in the initiation and propagation of atherosclerosis
What New Information Does This Article Contribute? 
 We performed a meta-analysis of six population-based cohort studies involving 17,000 stroke-
free individuals that were followed up for 16 years.
 After adjustment for traditional vascular risk factors, higher baseline MCP-1 levels were
associated with a higher risk of any stroke and ischemic stroke, but not hemorrhagic stroke over
follow-up.
 On top of experimental and genetic data, our findings provide additional evidence supporting
MCP-1 signaling as a promising target for lowering stroke risk
In view of recent findings suggesting the efficacy of anti-inflammatory approaches in lowering vascular 
risk, there is a need for identification of specific inflammatory mediators that show promise as potential 
therapeutic targets. Experimental and genetic evidence suggests MCP-1, a chemokine involved in monocyte 
recruitment, to play a critical role in atherosclerosis and stroke. Here, we aimed to amplify this concept by 
exploring in a meta-analysis of 6 previously unpublished cohort studies whether MCP-1 levels are 
associated with risk of stroke. Following up 17,000 stroke-free individuals for a mean of 16 years, we found 
baseline MCP-1 levels to be associated with a higher risk of any stroke, independently of traditional 
vascular risk factors. Across stroke subtypes, there was a significant association of MCP-1 levels with the 
risk of ischemic stroke, but not hemorrhagic stroke. Adjustments for interleukin-6 (IL-6) and C-reactive 
protein (CRP) levels did not attenuate these associations, thus indicating that MCP-1 signalling might 
contribute to stroke risk independently of the well-established IL-6-CRP axis. Along with genetic and 
experimental data, our findings provide triangulation of evidence suggesting MCP-1-as a causal risk factor 
for stroke and MCP-1 signaling as a potential therapeutic target. 
Table 1. Descriptive baseline characteristics of the six included population-based prospective cohort studies. 
Cohort ARIC DHS EPIC-Norfolk FHS Offspring MONICA/KORA MDCS-CV 
Geographical setting (baseline 
assessment) USA (1986-1989) USA (2000-2002) UK (1993-1997) USA (1998-2001) 
Germany (1984-
2002) Sweden (1991-1994) 
N individuals included in the 
analysis 1,234 2,931 3,182 3,069 2,055 4,709 
Follow-up (years) 23.0 [13.2-27.8] 11.0 (1.7) 16.8 (6.4) 13.8 (3.7) 15.7 (6.4) 19.5 (4.9) 
N incident stroke events 153 64 503 172 116 427 
N incident ischemic stroke events 141 42 458 141 99 352 
N incident hemorrhagic stroke 
events 12 9 76 22 17 69 
N fatal stroke events 10 6 132 26 22 30 
Age (years) 56.9 (5.3) 44.0 (10.0) 65.3 (7.8) 61.6 (9.4) 52.4 (10.3) 57.5 (4.9) 
Male sex (N, %) 738 (59.8) 1254 (42.8) 2009 (63.1) 1421 (46.3) 1093 (53.2) 1873 (39.8) 
Hypertension (N, %) 417 (33.9) 944 (32.7) 2029 (63.8) 1378 (44.9) 877 (42.7) 2958 (62.8) 
SBP (mmHg) 125 (20) 124 (19) 141 (18) 127 (19) 133 (19) 141 (19) 
DBP (mmHg) 74 (12) 78 (10) 85 (11) 74 (10) 82 (11) 87 (9) 
Diabetes (N, %) 156 (12.6) 296 (10.1) 623 (19.6) 379 (12.3) 103 (5.0) 183 (3.9) 
Hypercholesterolemia (N, %) 760 (61.6) 377 (12.9) 414 (13.0) 1615 (52.6) 1251 (57.4) 2918 (62.8) 
LDL cholesterol levels (mg/dL) 142.8 (39.9) 107.4 (35.3) 160.1 (39.4) 119.9 (32.7) 148.5 (2.4) 161.3 (37.9) 
HDL cholesterol levels (mg/dL) 49.6 (16.5) 50.0 (14.6) 51.8 (15.1) 53.9 (16.7) 56.0 (17.0) 53.8 (14.3) 
BMI (kg/m²) 27.4 (5.1) 29.7 (7.0) 26.6 (3.6) 28.1 (5.3) 27.2 (4.1) 25.6 (3.9) 
Smoking status (N, %)
Never smokers 461 (37.3) 1639 (55.9) 1201 (10.3) 1077 (35.1) 947 (46.1) 1916 (40.1) 
Ex-smokers 397 (32.2) 496 (16.9) 1652 (51.9) 1604 (52.3) 591 (28.8) 1777 (37.8) 
Current smokers 376 (30.5) 796 (27.2) 329 (37.7) 388 (12.6) 517 (25.1) 1010 (21.5) 
eGFR (mL/min/1.73 m²) 100.0 (16.6) 99.5 (23.7) 74.5 (24.9) 83.3 (16.5) 87.9 (17.4) 76.9 (15.3) 
Coronary artery disease (N, %) 68 (5.5) 79 (2.7) 0 (0) 265 (8.6) 46 (2.2) 78 (1.7) 
Atrial fibrillation (N, %) 1 (0.1) 35 (1.2) n/a 119 (3.9) n/a 34 (0.7) 
Heart failure (N, %) 53 (4.3) 83 (2.8) 0 (0) 31 (1.0) 119 (5.7) 2 (0.04)
hsCRP levels (mg/L) n/a 2.8 [1.2-6.8] 2.0 [1.0-3.8] 2.2 [1.0-5.1] 1.4 [0.7-3.3] 1.3 [0.7-2.7] 
Sample used for MCP-1 assessment plasma plasma serum serum serum plasma 
MCP-1 levels (pg/mL) 
398.9 [348.4-
467.1] 
166.5 [122.9-
224.4] 51.5 [38.8-68.1] 
313.4 [253.9-
382.3] 
298.0 [127.6-
323.8] 2.52 [2.22-2.82]* 
The numbers correspond to N (%) for categorical variables and to mean (SD) or median [25th - 75th percentile] for continuous variables. 
* The used assay in MDCS did not provide MCP-1 measurements as absolute values, but as relative expression levels obtained by proximity extension
assay (PEA). 
Abbreviations: ARIC, Atherosclerosis Risk in Communities Study; DHS, Dallas Heart Study; EPIC-Norfolk, European Prospective Investigation of Cancer, 
Norfolk; FHS Offspring, Framingham Heart Study- Offspring Cohort; MONICA/KORA, Monitoring of Trends and Determinants in Cardiovascular Disease 
- Kooperative Gesundheitsforschung in der Region Augsburg; MDCS-CV, Malmö Diet and Cancer Study – Cardiovascular sub-cohort; BMI, body mass 
index; hsCRP, high-sensitivity C-reactive protein; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; 
LDL, low-density liporprotein; MCP-1, monocyte chemoattractant protein- 1; SBP, systolic blood pressure.  
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